Eikon Therapeutics

EIKN · Nasdaq · United States

Share price · EIKN

$5.17-6.48 (-55.62%) 3M

close as of 2026-11-18 · 24h delayed · vol 392K (0.7x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when EIKN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+15.1%
  2. 26 Oct 2026-23.7%
  3. 23 Oct 2026-11.9%
  4. 16 Sep 2026-10.3%
  5. 10 Sep 2026-14.2%
  6. 25 Aug 2026+12.5%
  7. 18 Aug 2026+11.3%
  8. 27 Jul 2026+11.0%
  9. 26 Jun 2026+16.2%
  10. 12 May 2026+15.9%

Share of unusual movement by asset

For each asset, the share of EIKN's own-move activity since 6 Feb 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Resiquimod
events and moves
6shown from 8 days
Assets with fewer than 8 event days, together—16%
Other company news (earnings, financing, releases naming no asset)—15%
Sessions with no dated event—69%

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2/3
Toll-like receptor 7 and 8 (TLR7/8)Small molecule
Non-Small Cell Lung CancerMelanoma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
ResiquimodPhase 2NSCLC
Est. primary completion 2026-12 · NCT06246110 · CT.gov ↗
What to watch
2035 (2)
December 2035 (2)
ResiquimodPhase 2/3Advanced Melanoma
Est. primary completion 2035-12 · NCT06697301 · CT.gov ↗
What to watch
ResiquimodPhase 2/3Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC
Est. primary completion 2035-12-31 · NCT07365319 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

30 May 2026Topline resultEIK1001EIK1001-005 (NCT06246110) Phase 2 data at ASCO 2026: ORR 63.1%
Eikon Therapeutics · Source ↗

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$72M$98M+ $363M short-term inv.$86M-$69M operating cash flowreport ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$75M$143M+ $389M short-term inv.$88M-$65M operating cash flowreport ↗
2026-Q1$0—$596M$83Mreport ↗
2025-Q3—$59M$105M$71M-$60M operating cash flowreport ↗
2025-Q2—$69M$137M$105M-$33M operating cash flowreport ↗
2025-Q1—$57M$205M$68M-$55M operating cash flowreport ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$0$250M$336M$324Mreport ↗

Eikon Therapeutics reported full-year 2025 revenue of $0M, with R&D expenses of $250.3M, up 22% YoY, and cash, cash equivalents, and marketable securities of $336.0M as of December 31, 2025. The company reported a full-year net loss and comprehensive loss of $324.2M and a net loss attributable to common stockholders of $333.6M.

Eikon closed an upsized IPO in February 2026, raising $381.2M in gross proceeds, and expects current cash to fund operations into the second half of 2027. Enrollment was completed in the TeLuRide-005 Phase 2 trial of EIK1001 in first-line non-small cell lung cancer, with a comprehensive data set expected in 2H 2026. EIK1003 and EIK1004 are being evaluated in Phase 1/2 trials, with EIK1003 Cohort 1D initiation anticipated in 2H 2026. EIK1005 had a preclinical abstract accepted at the 2026 AACR annual meeting, and a Phase 1/2 trial is underway following completion of a healthy volunteer study. David W. Meline was elected as an independent director in December 2025.

Insider transactions

Open-market activity, trailing 12 months: 10 purchases ($52.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-09-03Column Group IV GP, LP; Column Group IV-A, LP; Column Group IV, LP; Column Group Opportunity III, LP; Column Group Opportunity III GP, LP; TCG Opportunity III GP, LLC; Kutzkey Tim; Svennilson Peter · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% ownerOpen-market purchase89,200$11.56$1.0MForm 4
2026-03-02Bowie Alfred Lloyd Jr. · Chief Financial OfficerAward / grant (derivative)67,044——Form 4
2026-03-02Baynes Roy D. · Chief Medical OfficerAward / grant (derivative)134,088——Form 4
2026-03-02Thorner Benjamin Bruno · See RemarksAward / grant (derivative)67,044——Form 4
2026-03-02PERLMUTTER ROGER M · director, See remarksAward / grant (derivative)268,176——Form 4
2026-03-02FRAZIER KENNETH C · directorAward / grant (derivative)25,873——Form 4
2026-03-02Huffines Robert Luther · directorAward / grant (derivative)25,873——Form 4
2026-03-02Klobuchar Michael A · Chief Operating OfficerAward / grant (derivative)87,157——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 52 reporting institutions held 23.7M shares ($228.0M, 43.8% of shares outstanding).

#InstitutionSharesValue
1FMR LLC3,836,830$40.6M
2BlackRock, Inc.3,319,379$35.1M
3Foresite Capital Management IV, LLC1,943,682$20.6M
4Merck & Co., Inc.1,666,666$17.6M
5Foresite Capital Management V, LLC1,318,983$14.0M
6Capital World Investors1,143,637$12.1M
7ALLIANCEBERNSTEIN L.P.1,022,188$10.8M
8VANGUARD CAPITAL MANAGEMENT LLC969,431$10.3M
9EcoR1 Capital, LLC732,606$7.8M
10BAKER BROS. ADVISORS LP555,555$5.9M
11SOROS CAPITAL MANAGEMENT LLC484,672$5.1M
12StepStone Group LP395,340$4.2M
13CANADA PENSION PLAN INVESTMENT BOARD379,024$4.0M
14FRANKLIN RESOURCES INC350,000$3.7M
15CITADEL ADVISORS LLC310,000$3.3M